RMANJ is redefining IVF in NJ and is committed to making it a more effective, safe, and successful experience with fertility treatment. Our comprehensive patient-centered care and fertility breakthroughs result in some of the highest IVF delivery rates in the US and the world.


We’re glad you found us here at Reproductive Medicine Associates of New Jersey (RMANJ). Maybe you’re new to infertility or perhaps you’re looking for more choices in fertility treatment in NJ. Either way, we understand. Despite having some of the highest in-vitro fertilization (IVF) delivery rates in the US and the world, we’re constantly looking for the safest and most effective techniques and technologies to help you increase your chances for a successful pregnancy and delivery, while giving you reasons to stay positive during your treatment. Advancements like extended embryo culture, trophectoderm biopsy, SelectCCS and single embryo transfer are just some of the ways that we’re helping to redefine the IVF experience and expectations of success in NJ.

Some of our team here at RMANJ were patients just like you, so we understand fertility treatment in NJ is often life-changing and emotional. We also understand that there are other things that are important during your cycle - family, friends, and work.

Patient centered care of fertility treatment in NJOur doctors – not technicians – conduct cycle monitoring 7 days a week, providing a higher level of personalized care and a chance to have those everyday questions answered every day. Our entire team takes pride in offering the simple touches and conveniences that help you stay positive.



IVF clinic and information in NJIn-Vitro Fertilization (IVF) is the most effective and most common fertility treatment today. The process starts in a laboratory with the fertilization of the egg, which forms an embryo. The embryo is then implanted in the uterus of the female carrier. RMANJ has greatly improved the effectiveness of this fertility treatment by developing technology that screens selected embryos in just four hours. This test identifies those with a normal number of chromosomes to implant in the uterus - scientifically supporting greater chances for a healthy pregnancy.


Improving Safety and Outcomes in IVF

Many IVF programs are still relying heavily on judging an embryo’s potential to implant by how it looks under the microscope, essentially judging a book by its cover. However, RMANJ led the development of a one-of-a-kind, well validated, 24-chromosome screening process called SelectCCS which identifies whether embryos have a normal number of chromosomes or have an abnormal number of chromosomes. Published data suggests that 50-70% of miscarriages are due to embryos with too few or too many chromosomes.

In 2013 RMANJ donated SelectCCS to the Foundation for Embryonic Competence (FEC), a non-profit organization dedicated to improving outcomes and advancing knowledge in the areas of research, diagnosis, and education. (www.feclabs.org)